GlobeNewsWire
06 Nov 2025, 21:01 UTC · 51w ago
Impact · against what's priced in
Positive Phase 2 results for silevertinib in frontline non-classical EGFRm NSCLC provide a material valuation catalyst for BDTX. The lack of de novo brain metastases specifically supports the drug's intended brain-penetrant profile.
No priced-in read yet
What the story claims
2 claims · scored −1 bearish … +1 bullish
Black Diamond Therapeutics reported positive Phase 2 results for silevertinib in frontline patients with non-classical EGFRm NSCLC, noting no patients developed de novo brain metastases.
More positive than 99% of claims this week
Black Diamond Therapeutics will participate in upcoming investor conferences with CEO Mark Velleca.
Continue reading
5 related stories
The reporting of positive Phase 2 results for silevertinib, particularly the observation that no patients developed de novo brain metastases, provides tangible clinical validation for the company's lead candidate.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
More positive than 38% of claims this week
Which stocks this story touches
More positive than 71% of ticker scores this week
The company is participating in investor conferences and reported positive Phase 2 results for silevertinib.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
7h ago
−52.3%
Price is moving against the score
$1.90 vs $3.98 close before publication (Nov 6) · not market-adjusted
BDTX chart →
